Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Completed

• Conditions: Asthma

• Registration Number: NCT00968305
• Lead Sponsor: Rush University Medical Center

Brief Summary

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

Detailed Description

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Study Timeline

• Study Start: 2008-11
• Status Verified: 2009-08
• Primary Completion: 2009-08
• Study Completion: 2009-08
• Study First Submitted: 2009-08-19
• Study First Submitted QC: 2009-08-26
• Last Update Submitted: 2009-08-26
• Study First Posted: 2009-08-28
• Last Update Posted: 2009-08-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• African-American race, born in the U.S.
• Age 8-15 years
• Clinical diagnosis of asthma
• Subject is able to understand and follow verbal instructions in English

Exclusion Criteria

• Asthma exacerbation in the 4 weeks preceding the research visit
• Oral/IV steroid use in the 4 weeks preceding the research visit
• Upper or lower respiratory tract infection in the 4 weeks preceding the research visit
• Antibiotic use in the 4 weeks preceding the research visit
• Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing)
• Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin-13 from phytohemagglutinin activated peripheral blood mononuclear cells	7 months (from the start to completion of study. The blood was drawn at the one and only visit for each subject)

Secondary Outcome Measures

Name	Time	Method
Lung function measured by percent predicted forced expiratory volume in the first second (FEV1%)	7 months (from the start to completion of study, but FEV1% was measured at the one and only visit for each subject)

Trial Locations

Locations (1)

Rush University Medical Center; Clinic: University Consultants in Allergy and Immunology; 🇺🇸 Chicago, Illinois, United States